Terms: = Thyroid cancer AND CIITA, P33076, 4261, ENSG00000179583, MHC2TA, C2TA
3 results:
1. Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression.
Gravina A; Tediashvili G; Rajalingam R; Quandt Z; Deisenroth C; Schrepfer S; Deuse T
Nat Biotechnol; 2023 May; 41(5):717-727. PubMed ID: 36593395
[TBL] [Abstract] [Full Text] [Related]
2. Risk-stratified papillary thyroid microcarcinoma: post-operative management and treatment outcome in a single center.
Kanokwongnuwat W; Larbcharoensub N; Sriphrapradang C; Suppasilp C; Thamnirat K; Sakulpisuti C; Kositwattanarerk A; Utamakul C; Sritara C; Chamroonrat W
Endocrine; 2022 Jun; 77(1):134-142. PubMed ID: 35476179
[TBL] [Abstract] [Full Text] [Related]
3. Identification of Novel Oncogenic Mutations in thyroid cancer.
Pitt SC; Hernandez RA; Nehs MA; Gawande AA; Moore FD; Ruan DT; Cho NL
J Am Coll Surg; 2016 Jun; 222(6):1036-1043.e2. PubMed ID: 27010584
[TBL] [Abstract] [Full Text] [Related]
